Artiva differentiates itself through scalable, off-the-shelf cell therapy manufacturing with no specialized oncology infrastructure requirements, enabling community-based administration. The company combines established manufacturing technology (licensed from GC Cell) with multiple clinical programs addressing both autoimmune diseases and hematologic/solid tumors through a dual-trial strategy.
Cyborg Score Rationale
Early-stage clinical company with strong safety data from autoimmune trials (no CRS/ICANS), FDA Fast Track designation for refractory RA, and a diversified pipeline. However, company is pre-revenue and deeply unprofitable with ~$67M market cap and ongoing funding dependency through near-term inflection points.
Top Insights
October 2025: Announced positive initial safety data from 32 autoimmune patients treated with AlloNK + anti-CD20 mAb showing consistent B-cell depletion with no cytokine-related toxicities
October 2025: Received FDA Fast Track Designation for AlloNK in refractory rheumatoid arthritis (RA), positioning for potential pivotal trial initiation
H1 2026 (expected): Company plans to present initial clinical response data and conduct FDA regulatory meetings for pivotal RA trial design alignment
Platform advantage: AlloNK demonstrated feasibility of community rheumatology site administration without specialized oncology oversight, reducing treatment barriers
Named Competitors
CAR-T Immunotherapies — Personalized autologous CAR-T cells for hematologic malignancies
NK Cell Therapies — Engineered NK cell therapies for cancer
B-Cell Depleting Therapies — Monoclonal antibodies targeting B cells in autoimmune disease
Recent Developments
(October 2025) Positive safety and translational data from AlloNK in autoimmune disease trials with deep B-cell depletion in all patients
(October 2025) FDA Fast Track Designation received for AlloNK in refractory rheumatoid arthritis
(August 2025) First patient dosed in company-sponsored global basket trial of AlloNK + rituximab
Open the full interactive Artiva Biotherapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.